Skip to main content

Glypican 3 Products

The glypicans (GPC) constitute a family of glycosylphosphatidylinositol (GPI)-anchored, heparan sulfate proteoglycans. Six members of this family have been identified in mammals (GPC1-GPC6). All glypican core proteins contain an N-terminal signal peptide, a large globular cysteine-rich domain (CRD) with 14 invariant cysteine residues, a stalk-like region containing the heparan sulfate attachment sites, and a C-terminal GPI attachment site.

Mutations in Glypican 3 cause a rare disorder in humans, Simpson-Golabi-Behmel Syndrome, which is characterized by pre- and postnatal overgrowth of multiple tissues and organs and an increased risk for developing embryonic tumors. These features are also present in the mouse knock-out of Glypican 3 indicating that Glypican 3 regulates cell survival and inhibits cell proliferation during development. Glypican 3 has been implicated in regulating many different signaling pathways including: IGF, FGF, BMP and Wnt. An endoproteolytic processing of Glypican 3 by proprotein convertases is required for the modulation of Wnt signaling. Direct interaction of Glypican 3 with FGF-basic has been observed and is mediated by the heparan sulfate chains.

Show More

367 results for "Glypican 3" in Products

Back to Search Results
Apply

367 results for "Glypican 3" in Products

Glypican 3 Products

The glypicans (GPC) constitute a family of glycosylphosphatidylinositol (GPI)-anchored, heparan sulfate proteoglycans. Six members of this family have been identified in mammals (GPC1-GPC6). All glypican core proteins contain an N-terminal signal peptide, a large globular cysteine-rich domain (CRD) with 14 invariant cysteine residues, a stalk-like region containing the heparan sulfate attachment sites, and a C-terminal GPI attachment site.

Mutations in Glypican 3 cause a rare disorder in humans, Simpson-Golabi-Behmel Syndrome, which is characterized by pre- and postnatal overgrowth of multiple tissues and organs and an increased risk for developing embryonic tumors. These features are also present in the mouse knock-out of Glypican 3 indicating that Glypican 3 regulates cell survival and inhibits cell proliferation during development. Glypican 3 has been implicated in regulating many different signaling pathways including: IGF, FGF, BMP and Wnt. An endoproteolytic processing of Glypican 3 by proprotein convertases is required for the modulation of Wnt signaling. Direct interaction of Glypican 3 with FGF-basic has been observed and is mediated by the heparan sulfate chains.

Show More
Applications: IHC, ICC/IF, Flow
Reactivity: Human, Rat
Applications: BA

His-tag

Applications: IHC, WB, ICC/IF, Flow
Reactivity: Human
Applications: IHC, WB, ELISA, ICC/IF, Flow, CyTOF-ready
Reactivity: Human, Mouse
Applications: BA

Biotinylated

Applications: ELISA, Ctrl

For use with catalog number DGLY30

Applications: ELISA, Flow, Func
Reactivity: Human

Recombinant Monoclonal Antibody

Applications: BA
Applications: ELISA
Applications: BA
Applications: IHC
Reactivity: Human
Applications: Flow
Reactivity: Human
Applications: IHC, ICC/IF, Flow, MA
Reactivity: Human, Rat
Applications: BA

His-tag

Applications: Flow
Reactivity: Human
Applications: Flow
Reactivity: Human
Applications: Flow
Reactivity: Human
Applications: IHC, ICC/IF, Flow
Reactivity: Human, Rat

Recombinant Monoclonal Antibody.

Applications: IHC, ICC/IF, Flow
Reactivity: Human
Results Per Page
5 10 25 50
/ 15